The Role of Machine Learning and Artificial Intelligence in Drug Discovery and Clinical Care of Pulmonary Hypertension
Heart Failure Clinics · 2026-07 · 22 (3) · 361-370
DOI: 10.1016/j.hfc.2026.02.009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Heart Failure Clinics, 2026-07. Verfasst von Evelyne Bischof und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Shanghai University of Medicine and Health Sciences; Department of Longevity Medicine at Sheba Longevity Center, She…. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Machine Learning, Artificial Intelligence, Drug Discovery. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Pulmonary hypertension (PH) is a severe and oftentimes fatal disease with a high degree of clinical variability. Its complexity necessitates a multifaceted approach, with clinical and prognostic results significantly improved with earlier identification and initiation of treatment. Developments in artificial intelligence (AI) and machine learning (ML) allow earlier diagnosis, individualized treatments, and new therapeutic options, which have already shown real potential to improve patient outcomes; such an intricate approach was not feasible before the AI innovations of the last decade. This article outlines the current applications of AI and ML for diagnostics, treatment optimization, surveillance, and drug discovery for PH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Medicine, Shanghai University of Medicine and Health Sciences; Department of Longevity Medicine at Sheba Longevity Center, Sheba Medical Center, Tel Hashomer, Israel; Grey School of Medicine, Tel…
- Department of Longevity Medicine at Sheba Longevity Center, Sheba Medical Center, Tel Hashomer, Israel; Grey School of Medicine, Tel Aviv University.
- Department of Biomedical Sciences, Physiology of Circulation, Kidney and Lung, University of Copenhagen, Denmark; Division of Clinical Paediatrics, Department of Women's and Children's Health, Karolinska Institutet, Sto…
Zitieren
APA
Bischof, E., Haber, C., & Lidströmer, N. (2026). The Role of Machine Learning and Artificial Intelligence in Drug Discovery and Clinical Care of Pulmonary Hypertension. Heart Failure Clinics, 22(3), 361-370. https://doi.org/10.1016/j.hfc.2026.02.009
Vancouver
Bischof E, Haber C, Lidströmer N. The Role of Machine Learning and Artificial Intelligence in Drug Discovery and Clinical Care of Pulmonary Hypertension. Heart Failure Clinics. 2026;22(3):361-370. doi:10.1016/j.hfc.2026.02.009
BibTeX
@article{Bischof2026,
author = {Bischof, Evelyne and Haber, Chaim and Lidströmer, Niklas},
title = {The Role of Machine Learning and Artificial Intelligence in Drug Discovery and Clinical Care of Pulmonary Hypertension},
journal = {Heart Failure Clinics},
year = {2026},
volume = {22},
number = {3},
pages = {361--370},
doi = {10.1016/j.hfc.2026.02.009}
}
EUVIMED